title: The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France.
abstract: OBJECTIVE
  The main objective of the SCOPE study was to estimate the total direct medical costs of patients with treated chronic obstructive pulmonary disease (COPD) in France according to severity stages.
  
  
  METHODS
  Total medical resources consumption of a sample of COPD patients was collected over a 12-month period through a national physician survey (including both general practitioners and lung specialists). This survey was completed for 255 patients. Data were then extrapolated to all patients with diagnosed and treated COPD in France. Average total medical resources consumption of a COPD patient per year was 4366 euros. Among this cost 41% was directly related to COPD follow-up, 25% to COPD-related complications (mainly exacerbations), and 34% to other diseases. More than one-third of the total direct COPD cost was related to hospitalizations and 31% to drug consumption. COPD-related costs increased markedly with severity based on FEV1 (but data suggested the existence of a threshold effect). SCOPE data did not show any evidence of a significant relationship between direct medical cost and patient age, sex, addiction to tobacco, or duration of COPD. The total medical consumption of COPD patients in France was 3.5 billion euros and accounted for 3.5% of the total medical expenditures (prevalence of COPD was estimated 1.3% in the general population).
  
  
  RESULTS
  The SCOPE study revealed the high level of medical resources consumption of patients with COPD.
  
  
  CONCLUSIONS
  The burden of COPD itself and its complications appeared to be of considerable magnitude in France especially for severe COPD.
authors.affiliation: Cemka-Eval (Consultancy in Health Economics), Bourg-la-Reine, France. bruno.detournay@cemka.fr
authors.forename: B
authors.initials: B
authors.lastname: Detournay
authors.forename: C
authors.initials: C
authors.lastname: Pribil
authors.forename: M
authors.initials: M
authors.lastname: Fournier
authors.forename: B
authors.initials: B
authors.lastname: Housset
authors.forename: G
authors.initials: G
authors.lastname: Huchon
authors.forename: D
authors.initials: D
authors.lastname: Huas
authors.forename: P
authors.initials: P
authors.lastname: Godard
authors.forename: C
authors.initials: C
authors.lastname: Voinet
authors.forename: I
authors.initials: I
authors.lastname: Chanal
authors.forename: Colette
authors.initials: C
authors.lastname: Jourdanne
authors.forename: I
authors.initials: I
authors.lastname: Durand-Zaleski
mesh_terms: D000368:Aged; D015897:Comorbidity; D017281:Cost of Illness; D004180:Direct Service Costs; D005260:Female; D005602:France; D006296:Health Services / Q000706:statistics & numerical data*; D006302:Health Services Research; D006801:Humans; D008297:Male; D008875:Middle Aged; D019370:Observation; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive / Q000145:classification / Q000191:economics* / Q000473:pathology; D012123:Pulmonary Ventilation; D012720:Severity of Illness Index; D012907:Smoking / Q000009:adverse effects